Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Simvastatin in patients with progressive multiple sclerosis.
Identifying Modulators of CXC Receptors 3 and 4 with Tailored Selectivity using Multi-Target Docking.
Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Profile of Differential Promoter Activity by Nucleotide Substitution at GWAS Signals For Multiple Sclerosis.
Intention tremor and deficits of sensory feedback control in multiple sclerosis: a pilot study.
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings.
(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.
Analysis of polymorphisms in RIG-I-like receptor genes in German multiple sclerosis patients.
Cardiovascular effects of fingolimod: A review article.
cFLIP is critical for oligodendrocyte protection from inflammation.
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.
Chronic primary central nervous system histoplasmosis in a healthy child with intermittent neurological manifestations.
[Acute transverse myelitis after allogeneic bone marrow transplantation for acute lymphoblastic leukemia--a case report].
A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK.
Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis.
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis
Essential oil from Pterodon emarginatus seeds ameliorates experimental autoimmune encephalomyelitis by modulating Th1/Treg cell balance.
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies.
[Progressive multifocal leukoencephalopathy (review)].
Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment.
Drugs in Development for Relapsing Multiple Sclerosis.
Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS).
Cognitive Trajectories in 4 Patients With Pediatric-Onset Multiple Sclerosis: Serial Evaluation Over a Decade.
Pages
« first
‹ previous
…
372
373
374
375
376
377
378
379
380
…
next ›
last »